Omnicell, Inc. Logo

Omnicell, Inc.

OMCL

(1.0)
Stock Price

44,98 USD

-1.6% ROA

-1.47% ROE

-95.26x PER

Market Cap.

1.979.573.152,00 USD

48.36% DER

0% Yield

-1.66% NPM

Omnicell, Inc. Stock Analysis

Omnicell, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Omnicell, Inc. Fundamental Stock Analysis
# Analysis Rating
1 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

2 PBV

The stock's PBV ratio (1.26x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

3 DER

The stock maintains a fair debt to equity ratio (51%), indicating a reasonable balance between the money it owes and the ownership it possesses.

4 ROE

The stock's ROE indicates a negative return (-2.98%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-2.71%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Graham Number

The company's Graham number indicates that it is overvalued compared to its stock price, suggesting a potentially unfavorable investment opportunity.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (-1.893), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Omnicell, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Omnicell, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Omnicell, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Omnicell, Inc. Revenue
Year Revenue Growth
2000 67.365.000
2001 86.901.000 22.48%
2002 87.690.000 0.9%
2003 102.127.000 14.14%
2004 123.939.000 17.6%
2005 121.518.000 -1.99%
2006 154.710.000 21.45%
2007 213.081.000 27.39%
2008 251.865.000 15.4%
2009 213.457.000 -17.99%
2010 222.407.000 4.02%
2011 245.535.000 9.42%
2012 314.027.000 21.81%
2013 380.585.000 17.49%
2014 440.900.000 13.68%
2015 484.559.000 9.01%
2016 692.623.000 30.04%
2017 716.165.000 3.29%
2018 787.309.000 9.04%
2019 897.027.000 12.23%
2020 892.208.000 -0.54%
2021 1.132.018.000 21.18%
2022 1.295.947.000 12.65%
2023 1.194.652.000 -8.48%
2023 1.147.112.000 -4.14%
2024 1.107.152.000 -3.61%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Omnicell, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2000 11.273.000
2001 11.031.000 -2.19%
2002 9.970.000 -10.64%
2003 8.950.000 -11.4%
2004 9.105.000 1.7%
2005 9.611.000 5.26%
2006 11.222.000 14.36%
2007 15.050.000 25.44%
2008 18.196.000 17.29%
2009 17.569.000 -3.57%
2010 21.007.000 16.37%
2011 22.042.000 4.7%
2012 23.726.000 7.1%
2013 29.105.000 18.48%
2014 27.802.000 -4.69%
2015 35.160.000 20.93%
2016 57.799.000 39.17%
2017 66.022.000 12.45%
2018 64.843.000 -1.82%
2019 68.644.000 5.54%
2020 70.161.000 2.16%
2021 75.716.000 7.34%
2022 104.969.000 27.87%
2023 97.124.000 -8.08%
2023 93.286.000 -4.11%
2024 84.408.000 -10.52%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Omnicell, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 138.295.000 100%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Omnicell, Inc. EBITDA
Year EBITDA Growth
2000 -10.062.000
2001 2.993.000 436.18%
2002 1.995.000 -50.03%
2003 12.394.000 83.9%
2004 14.949.000 17.09%
2005 2.254.000 -563.22%
2006 12.891.000 82.51%
2007 22.864.000 43.62%
2008 13.958.000 -63.81%
2009 2.776.000 -402.81%
2010 11.409.000 75.67%
2011 16.355.000 30.24%
2012 27.083.000 39.61%
2013 35.299.000 23.28%
2014 49.583.000 28.81%
2015 67.385.000 26.42%
2016 64.843.000 -3.92%
2017 57.265.000 -13.23%
2018 95.742.000 40.19%
2019 142.473.000 32.8%
2020 107.121.000 -33%
2021 174.438.000 38.59%
2022 96.846.000 -80.12%
2023 109.068.000 11.21%
2023 76.229.000 -43.08%
2024 104.124.000 26.79%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Omnicell, Inc. Gross Profit
Year Gross Profit Growth
2000 40.787.000
2001 54.134.000 24.66%
2002 51.272.000 -5.58%
2003 59.666.000 14.07%
2004 71.906.000 17.02%
2005 67.010.000 -7.31%
2006 85.521.000 21.64%
2007 113.309.000 24.52%
2008 128.634.000 11.91%
2009 105.221.000 -22.25%
2010 117.917.000 10.77%
2011 135.784.000 13.16%
2012 170.554.000 20.39%
2013 203.399.000 16.15%
2014 233.860.000 13.03%
2015 247.930.000 5.67%
2016 313.800.000 20.99%
2017 322.088.000 2.57%
2018 372.330.000 13.49%
2019 436.912.000 14.78%
2020 413.292.000 -5.72%
2021 554.653.000 25.49%
2022 588.987.000 5.83%
2023 527.856.000 -11.58%
2023 499.929.000 -5.59%
2024 457.404.000 -9.3%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Omnicell, Inc. Net Profit
Year Net Profit Growth
2000 -20.789.000
2001 -1.167.000 -1681.41%
2002 -5.038.000 76.84%
2003 7.307.000 168.95%
2004 10.602.000 31.08%
2005 -2.074.000 611.19%
2006 10.365.000 120.01%
2007 43.295.000 76.06%
2008 12.724.000 -240.26%
2009 444.000 -2765.77%
2010 4.892.000 90.92%
2011 10.389.000 52.91%
2012 16.161.000 35.72%
2013 23.979.000 32.6%
2014 30.518.000 21.43%
2015 30.760.000 0.79%
2016 603.000 -5001.16%
2017 20.605.000 97.07%
2018 37.729.000 45.39%
2019 61.338.000 38.49%
2020 32.194.000 -90.53%
2021 77.849.000 58.65%
2022 5.648.000 -1278.35%
2023 22.212.000 74.57%
2023 -20.371.000 209.04%
2024 14.940.000 236.35%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Omnicell, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2000 -12
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 1 100%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 0 0%
2017 1 0%
2018 1 0%
2019 1 100%
2020 1 0%
2021 2 100%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Omnicell, Inc. Free Cashflow
Year Free Cashflow Growth
2000 -19.619.000
2001 -13.657.000 -43.66%
2002 -890.000 -1434.49%
2003 5.022.000 117.72%
2004 -8.083.000 162.13%
2005 -4.356.000 -85.56%
2006 15.721.000 127.71%
2007 30.259.000 48.05%
2008 7.205.000 -319.97%
2009 39.374.000 81.7%
2010 13.511.000 -191.42%
2011 18.131.000 25.48%
2012 18.882.000 3.98%
2013 34.811.000 45.76%
2014 42.561.000 18.21%
2015 13.673.000 -211.28%
2016 18.772.000 27.16%
2017 -5.707.000 428.93%
2018 49.592.000 111.51%
2019 83.344.000 40.5%
2020 131.004.000 36.38%
2021 173.474.000 24.48%
2022 17.041.000 -917.98%
2023 126.078.000 86.48%
2023 42.820.000 -194.44%
2024 45.151.000 5.16%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Omnicell, Inc. Operating Cashflow
Year Operating Cashflow Growth
2000 -19.108.000
2001 -10.710.000 -78.41%
2002 1.183.000 1005.33%
2003 7.681.000 84.6%
2004 -4.302.000 278.54%
2005 -2.258.000 -90.52%
2006 19.507.000 111.58%
2007 37.227.000 47.6%
2008 19.535.000 -90.57%
2009 43.130.000 54.71%
2010 20.599.000 -109.38%
2011 31.243.000 34.07%
2012 39.484.000 20.87%
2013 55.263.000 28.55%
2014 65.163.000 15.19%
2015 33.762.000 -93.01%
2016 47.937.000 29.57%
2017 24.834.000 -93.03%
2018 103.966.000 76.11%
2019 145.008.000 28.3%
2020 185.870.000 21.98%
2021 231.809.000 19.82%
2022 77.781.000 -198.03%
2023 181.094.000 57.05%
2023 57.007.000 -217.67%
2024 58.700.000 2.88%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Omnicell, Inc. Capital Expenditure
Year Capital Expenditure Growth
2000 511.000
2001 2.947.000 82.66%
2002 2.073.000 -42.16%
2003 2.659.000 22.04%
2004 3.781.000 29.67%
2005 2.098.000 -80.22%
2006 3.786.000 44.59%
2007 6.968.000 45.67%
2008 12.330.000 43.49%
2009 3.756.000 -228.27%
2010 7.088.000 47.01%
2011 13.112.000 45.94%
2012 20.602.000 36.36%
2013 20.452.000 -0.73%
2014 22.602.000 9.51%
2015 20.089.000 -12.51%
2016 29.165.000 31.12%
2017 30.541.000 4.51%
2018 54.374.000 43.83%
2019 61.664.000 11.82%
2020 54.866.000 -12.39%
2021 58.335.000 5.95%
2022 60.740.000 3.96%
2023 55.016.000 -10.4%
2023 14.187.000 -287.79%
2024 13.549.000 -4.71%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Omnicell, Inc. Equity
Year Equity Growth
2000 -25.024.000
2001 19.601.000 227.67%
2002 16.306.000 -20.21%
2003 34.758.000 53.09%
2004 53.697.000 35.27%
2005 55.238.000 2.79%
2006 89.996.000 38.62%
2007 254.639.000 64.66%
2008 233.557.000 -9.03%
2009 242.304.000 3.61%
2010 265.493.000 8.73%
2011 282.914.000 6.16%
2012 307.584.000 8.02%
2013 348.334.000 11.7%
2014 390.098.000 10.71%
2015 402.388.000 3.05%
2016 431.607.000 6.77%
2017 517.199.000 16.55%
2018 679.617.000 23.9%
2019 845.254.000 19.6%
2020 967.503.000 12.64%
2021 1.146.689.000 15.63%
2022 1.130.137.000 -1.46%
2023 1.187.436.000 4.83%
2023 1.188.954.000 0.13%
2024 1.202.808.000 1.15%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Omnicell, Inc. Assets
Year Assets Growth
2000 43.905.000
2001 72.114.000 39.12%
2002 65.542.000 -10.03%
2003 84.467.000 22.41%
2004 99.491.000 15.1%
2005 100.428.000 0.93%
2006 154.630.000 35.05%
2007 328.423.000 52.92%
2008 309.091.000 -6.25%
2009 321.339.000 3.81%
2010 343.303.000 6.4%
2011 361.968.000 5.16%
2012 443.731.000 18.43%
2013 492.501.000 9.9%
2014 560.214.000 12.09%
2015 578.747.000 3.2%
2016 935.103.000 38.11%
2017 980.304.000 4.61%
2018 1.081.242.000 9.34%
2019 1.240.810.000 12.86%
2020 1.824.504.000 31.99%
2021 2.142.496.000 14.84%
2022 2.210.758.000 3.09%
2023 2.221.575.000 0.49%
2023 2.226.878.000 0.24%
2024 2.291.657.000 2.83%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Omnicell, Inc. Liabilities
Year Liabilities Growth
2000 68.929.000
2001 52.513.000 -31.26%
2002 49.236.000 -6.66%
2003 49.709.000 0.95%
2004 45.794.000 -8.55%
2005 45.190.000 -1.34%
2006 64.634.000 30.08%
2007 73.784.000 12.4%
2008 75.534.000 2.32%
2009 79.035.000 4.43%
2010 77.810.000 -1.57%
2011 79.054.000 1.57%
2012 136.147.000 41.93%
2013 144.167.000 5.56%
2014 170.116.000 15.25%
2015 176.359.000 3.54%
2016 503.496.000 64.97%
2017 463.105.000 -8.72%
2018 401.625.000 -15.31%
2019 395.556.000 -1.53%
2020 857.001.000 53.84%
2021 995.807.000 13.94%
2022 1.080.621.000 7.85%
2023 1.034.139.000 -4.49%
2023 1.037.924.000 0.36%
2024 1.088.849.000 4.68%

Omnicell, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
23.51
Net Income per Share
-0.45
Price to Earning Ratio
-95.26x
Price To Sales Ratio
1.83x
POCF Ratio
9.69
PFCF Ratio
13.06
Price to Book Ratio
1.64
EV to Sales
1.87
EV Over EBITDA
15.51
EV to Operating CashFlow
9.88
EV to FreeCashFlow
13.3
Earnings Yield
-0.01
FreeCashFlow Yield
0.08
Market Cap
1,98 Bil.
Enterprise Value
2,02 Bil.
Graham Number
16.31
Graham NetNet
-5.68

Income Statement Metrics

Net Income per Share
-0.45
Income Quality
-9.83
ROE
-0.02
Return On Assets
-0.01
Return On Capital Employed
-0.02
Net Income per EBT
1.07
EBT Per Ebit
0.51
Ebit per Revenue
-0.03
Effective Tax Rate
-0.07

Margins

Sales, General, & Administrative to Revenue
0.1
Research & Developement to Revenue
0.09
Stock Based Compensation to Revenue
0.04
Gross Profit Margin
0.41
Operating Profit Margin
-0.03
Pretax Profit Margin
-0.02
Net Profit Margin
-0.02

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
4.44
Free CashFlow per Share
3.3
Capex to Operating CashFlow
0.26
Capex to Revenue
0.05
Capex to Depreciation
0.32
Return on Invested Capital
-0.02
Return on Tangible Assets
-0.02
Days Sales Outstanding
85.71
Days Payables Outstanding
28.67
Days of Inventory on Hand
53.74
Receivables Turnover
4.26
Payables Turnover
12.73
Inventory Turnover
6.79
Capex per Share
1.14

Balance Sheet

Cash per Share
12,86
Book Value per Share
26,17
Tangible Book Value per Share
4.51
Shareholders Equity per Share
26.17
Interest Debt per Share
13.04
Debt to Equity
0.48
Debt to Assets
0.25
Net Debt to EBITDA
0.29
Current Ratio
2.45
Tangible Asset Value
0,21 Bil.
Net Current Asset Value
-0,09 Bil.
Invested Capital
1721595000
Working Capital
0,59 Bil.
Intangibles to Total Assets
0.43
Average Receivables
0,26 Bil.
Average Payables
0,05 Bil.
Average Inventory
98364000
Debt to Market Cap
0.29

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Omnicell, Inc. Dividends
Year Dividends Growth

Omnicell, Inc. Profile

About Omnicell, Inc.

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.

CEO
Mr. Randall A. Lipps
Employee
3.660
Address
590 East Middlefield Road
Mountain View, 94043

Omnicell, Inc. Executives & BODs

Omnicell, Inc. Executives & BODs
# Name Age
1 Mr. Brian H. Nutt
Vice President, Chief Accounting Officer & Corporate Controller
70
2 Mr. Nchacha E. Etta
Executive Vice President & Chief Financial Officer
70
3 Mr. Corey J. Manley
Executive Vice President, Chief Legal & Administrative Officer and Corporate Secretary
70
4 Mr. Nnamdi Njoku
Executive Vice President & Chief Operating Officer
70
5 Ms. Sara Dalmasso
Senior Vice President & GM of International
70
6 Ms. Minoo Mortazavi
Senior Vice President of Global Operations
70
7 Mr. Maximo Rocha
Senior Vice President & Chief People Officer
70
8 Mr. Randall A. Lipps
Founder, Executive Chairman, President & Chief Executive Officer
70
9 Mr. Giri Chodavarapu
Senior Vice President & Chief Information Officer
70
10 Ms. Kathleen Nemeth
Senior Vice President of Investor Relations
70

Omnicell, Inc. Competitors